|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
FR2459619B1
(fr)
|
1979-06-26 |
1983-07-29 |
Agronomique Inst Nat Rech |
Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
|
|
US4350156A
(en)
|
1980-05-29 |
1982-09-21 |
Japan Foundation For Artificial Organs |
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
|
|
US4455256A
(en)
|
1981-05-05 |
1984-06-19 |
The Regents Of The University Of California |
Bone morphogenetic protein
|
|
DE69427226T2
(de)
|
1993-03-24 |
2001-08-30 |
Owen Mumford Ltd., Woodstock |
Vorrichtung zur injektion
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
|
DE19543737A1
(de)
|
1995-11-24 |
1997-05-28 |
Hoechst Ag |
Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
SI1115743T1
(sl)
|
1998-09-25 |
2010-01-29 |
Yeda Res And Dev Co Ltd The We |
Polipeptidi, sorodni kopolimeru 1, za uporabo kot markerji molekulske mase in za terapevtsko uporabo
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
CA2355400A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co., Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
WO2001060392A1
(en)
|
2000-02-18 |
2001-08-23 |
Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
CA2411536A1
(en)
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
DE10158009A1
(de)
*
|
2001-11-21 |
2003-05-28 |
Begerow E Gmbh & Co |
Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen
|
|
SI1459065T1
(sl)
|
2001-12-04 |
2010-11-30 |
Teva Pharma |
Postopki za merjenje potentnosti glatiramer acetata
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
US7777006B2
(en)
|
2002-12-31 |
2010-08-17 |
Csl Behring L.L.C. |
Method for purification of alpha-1-antitrypsin
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
EP1603530A1
(en)
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PT1638589E
(pt)
|
2003-05-14 |
2014-06-12 |
Teva Pharma |
Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
|
|
RU2426590C2
(ru)
|
2003-07-18 |
2011-08-20 |
Бакстер Интернэшнл Инк. |
Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
|
|
US20050170004A1
(en)
|
2003-10-31 |
2005-08-04 |
Vered Rosenberger |
Nanoparticles for drug delivery
|
|
EP1701971A2
(en)
|
2003-12-31 |
2006-09-20 |
F.Hoffmann-La Roche Ag |
Peptide synthesis using decanting filter
|
|
AU2005218625A1
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20090048181A1
(en)
|
2004-09-02 |
2009-02-19 |
Schipper Hyman M |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
WO2006029411A2
(en)
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
|
US7495072B2
(en)
|
2004-09-09 |
2009-02-24 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
AU2005302500B2
(en)
|
2004-10-29 |
2008-11-27 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
KR20070108388A
(ko)
|
2005-02-02 |
2007-11-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
PL1848415T3
(pl)
|
2005-02-17 |
2013-10-31 |
Teva Pharma |
Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
|
|
WO2006116602A2
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
WO2008006026A1
(en)
|
2006-07-05 |
2008-01-10 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
|
CN100569282C
(zh)
|
2006-10-13 |
2009-12-16 |
俞嘉林 |
注射用骨肽冻干剂及其制备方法
|
|
WO2008157697A2
(en)
|
2007-06-21 |
2008-12-24 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
US8993722B2
(en)
|
2007-07-31 |
2015-03-31 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
US20090149541A1
(en)
|
2007-11-28 |
2009-06-11 |
Yafit Stark |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
KR101534422B1
(ko)
|
2008-05-14 |
2015-07-09 |
오토노미, 인코포레이티드 |
귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
|
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
|
RS52367B
(sr)
|
2009-07-15 |
2012-12-31 |
Teva Pharmaceutical Industries Ltd. |
Formulacije glatiramer acetata smanjene zapremine i postupci primene
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
ES2612001T4
(es)
|
2009-08-20 |
2018-02-07 |
Yeda Research & Development Company, Ltd. |
Terapia de baja frecuencia con acetato de glatirámero
|
|
ITMI20092069A1
(it)
|
2009-11-25 |
2011-05-26 |
Biofer Spa |
Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
NZ703122A
(en)
|
2010-10-11 |
2016-06-24 |
Teva Pharma |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
CA2827275A1
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
US8575198B1
(en)
*
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
KR20140101730A
(ko)
|
2011-10-10 |
2014-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
|
|
EP2869903B1
(en)
*
|
2012-07-06 |
2018-11-28 |
3-D Matrix Ltd. |
Fill-finish process for peptide solutions
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
JP2016504039A
(ja)
|
2013-01-04 |
2016-02-12 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマーアセテート関連医薬品の特性決定
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
MX2015012156A
(es)
|
2013-03-12 |
2015-11-30 |
Teva Pharma |
Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|